Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

PRCYTOMAG-40K

Millipore

MILLIPLEX® Non-Human Primate Cytokine Magnetic Bead Panel - Immunology Multiplex Assay

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in mouse serum, plasma and cell culture samples.

Synonym(s):

Luminex® non-human primate cytokine immunoassay, Millipore non-human primate cytokine panel, Monkey cytokine multiplex kit

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.47

Quality Level

species reactivity

nonhuman primates

manufacturer/tradename

Milliplex®

assay range

accuracy: 70-101%
standard curve range: 12.2-50,000 pg/mL
(IL-10, IL-18)

standard curve range: 2.4-10,000 pg/mL
standard curve range: 4.9-20,000 pg/mL
(IL-4)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

ambient

General description

The immune system is an organized complex network of biological structures and processes that protect against disease. For example, cytokine and chemokines mediate interactions between cells directly, regulating target immune cell responses. These responses result in inflammation where the immune system attempts to eradicate foreign antigens and begin the healing process. Consequently, the inflammatory process plays a key protective role in immunity. In addition, cytokine and chemokine research is essential in understanding the immune system and its multi-faceted response to most antigens, as well as disease states such as autoimmune disease, allergic reactions, sepsis, and cancer.

The MILLIPLEX® Non-Human Primate Cytokine panel is to be used for the simultaneous quantification of any or all of the following in tissue/cell lysate and culture supernatant samples and serum or plasma samples: G-CSF, GM-CSF, IFNγ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL8, IL-10, IL-12/23(p40), IL-13, IL-15, IL-17A, MCP-1, MIP-1β, MIP-1α, sD40L, TGF-α, TNF-α, VEGF, and IL-18.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Specificity

Cross Reactivty
The multiplexed assay panel has been tested with samples from multiple non-human
primate species, please see protocol for details.
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: G-CSF, GM-CSF, IFN-γ, IL-1RA, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23 (p40), IL-13, IL-15, IL-17, IL-18, MCP-1, MIP-1α, MIP-1β, sCD40L, TGF-α, TNF-α, VEGF
  • Recommended Sample type: Serum, plasma, and cell culture
  • Recommended Sample dilution: Neat
  • Assay Run Time: Overnight or one day. For best results, an overnight incubation is recommended
  • Research Category: Inflammation & Immunology

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Packaging

Everything you need in a single kit.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Sensitivity: Refer to kit protocol for sensitivities for individual cytokines/chemokines
Standard Curve Range: Refer to QC analysis sheet for exact concentration (sCD40L, TNFα)

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

G-CSF, GM-CSF, IFN-γ, IL-1ra, IL-1ß, IL-2, IL-5, IL-6, IL-8, IL-12/23 (p40), IL-13, IL-15, IL-17, MCP-1, MIP-1α, MIP-1ß, TGF-α, VEGF
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

10 - Combustible liquids


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Manutsanun Inthawong et al.
PLoS neglected tropical diseases, 16(8), e0010611-e0010611 (2022-08-05)
Scrub typhus is a vector-borne febrile illness caused by Orientia tsutsugamushi transmitted by the bite of Trombiculid mites. O. tsutsugamushi has a high genetic diversity and is increasingly recognized to have a wider global distribution than previously assumed. We evaluated
Olivier Demaria et al.
Cell reports. Medicine, 3(10), 100783-100783 (2022-10-20)
Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, the β-chain of the interleukin-2 receptor (IL-2R), and a tumor-associated antigen
Whitney A Nichols et al.
American journal of reproductive immunology (New York, N.Y. : 1989), 74(6), 508-522 (2015-08-21)
HIV infection among women is frequently modeled in female rhesus macaques. Longitudinal studies on genital compartment and hormonal factors that can influence susceptibility to SIV infection are lacking in this animal model. Genital specimens and menstruation of indoor-housed female rhesus
Tianhong Xie et al.
Signal transduction and targeted therapy, 7(1), 61-61 (2022-02-27)
Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2. To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants, we vaccinated rhesus monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine, followed by challenging with emerging SARS-CoV-2 variants
Johannes Lutz et al.
NPJ vaccines, 2, 29-29 (2017-12-22)
mRNA represents a promising new vaccine technology platform with high flexibility in regard to development and production. Here, we demonstrate that vaccines based on sequence optimized, chemically unmodified mRNA formulated in optimized lipid nanoparticles (LNPs) are highly immunogenic and well

Related Content

Learn the benefits of using biomarker detection multiplex immunoassays for laboratory, companion, and agricultural animal research and explore MILLIPLEX® multiplex assays for veterinary medicine and animal health research.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service